JP Morgan Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $550
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott maintains an Overweight rating on IDEXX Laboratories (NASDAQ:IDXX) but lowers the price target from $600 to $550.
November 02, 2023 | 9:44 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan maintains an Overweight rating on IDEXX Laboratories but lowers the price target from $600 to $550. This could potentially impact the stock's performance.
The news is directly related to IDEXX Laboratories. While the Overweight rating is maintained, the lowering of the price target could potentially create some uncertainty among investors, possibly affecting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100